08:36 AM EDT, 07/09/2024 (MT Newswires) -- Immunic ( IMUX ) said Tuesday it has appointed Jason Tardio as chief operating officer and president, starting July 12.

Tardio most recently served as chief operating officer at Ovid Therapeutics ( OVID ) , according to Immunic ( IMUX ).

The company also said Werner Gladdines, who is currently vice president for program management and clinical development operations, has been appointed chief development officer.

Shares of Immunic ( IMUX ) and Ovid were down marginally and 2.5% respectively in Tuesday premarket activity.